Skip to content
Article

The Grünhorn and Canymed Edge: Introducing Germany to SOMAÍ Extracts

Jan. 08, 2025 by SOMAÍ Pharmaceuticals

Germany is one of the fastest-growing global medical cannabis markets. Recent changes in cannabis legislation have allowed doctors to more liberally prescribe cannabis without the stigma of a narcotic. Not only is this a proper European Union policy, it is one that all global markets are watching and emulating.

There are a few big companies in Germany, but the largest and most unique model is Grünhorn and Canymed GmbH. Under their shared umbrella, Grünhorn Group, SOMAÍ extracts shot up to the number-one self-payer-sold extracts and ranked fourth in overall volume in just the first seven months of launch. Germany has a highly developed self-payer medical market for flower prescriptions, but extracts and dronabinol are mostly reimbursed.

SOMAu00cdu2019s Quality, Effect and Taste: Superior Cannabis Extracts

There are approximately ten extract brands in the market, and differentiation is required to succeed. The purity of SOMAÍ’s extract is easy to see with its clear color, which has earned SOMAÍ the title of the best pharmaceutical-grade extract with a good taste.

Many people talk about the “quality” of old raw extract products, but only a few other manufacturers can match the pure taste and high pharmaceutical quality of SOMAÍ extracts at significantly higher prices. Patient perceptions are paramount, and taste is essential for patient compliance with a regimen. Bringing consistent quality, high performance and good taste — all at an economical price — is the golden triangle to enter the pharmaceutical cannabis market successfully.

Gru00fcnhorn and Canymedu2019s Ingenuity Shine on the German Market

The Grünhorn Group, with its online pharmacy, gruenhorn.de, and its wholesaler and manufacturer, Canymed GmbH, combine online sales and salespeople in the field to propel medical extracts sales.

Data-Gathering and Technical Prowess

Each German directional region is different and requires distinct approaches: The east prefers dronabinol; the north is partial to extracts and flower; the west and south predominantly pursue flower. Mapping these regions and gathering data ensures scalability. In addition, Grünhorn works as an enablement platform that delivers resources by taking SOMAÍ’s culture and inserting it into German culture.

This combination of human ingenuity, technology, and art creates a flexible platform to enter Germany and connect with German pharmacies and patients — a translation machine, if you will. SOMAÍ products are scalable, and with each country having its own way of interpreting pharmaceutical information, it requires a skilled operator like Grünhorn and Canymed to make that connection.

A First-Mover Advantage Enables Patient-Centric Entrepreneurial Practices

Grünhorn and Canymed have succeeded because they are customer-centric to patients and try to solve their issues. The online pharmacy “Grünhorn Apotheke” was beneficial in the early days because it was tough for patients to get cannabis from their local, smaller pharmacies. In early 2020, they moved away from plastic bags or jars, which were unsuitable for the environment or product presentation, and invested in glass jars, which keep the product quality, protect the trichomes and thus the THC content of the flowers, and have a novel appearance. In addition, their first-mover advantage enabled them to become known for true quality.

Canymed Founder and Managing Director Matthias Fischer said that they have an extremely long-term vision: They consider cannabis to be a 6,000-year-old product in need of a 5- to 10-year business plan, and that Grünhorn and Canymed operate as if they seek to be the last product standing. He predicts that the future of German cannabis will be a pure medical market and that Germany will stay as it is. He envisions clear political strategies that will make a better and better medical market. With good actors and players, the medical cannabis market in Germany will be the best market for entrepreneurial pursuits.

Setting a Standard in German Medical Cannabis

With the Grünhorn and Canymed partnership, SOMAÍ’s extract portfolio will continue to reach patients so they can have a better-quality standard at a fair price. There is no reason medicine should taste bad, and using full-bud, single-strain extract lines with a three-step extraction process will bring consistent quality with the highest performance. SOMAÍ has invested in many future products for Germany and the global markets in its state-of-the-art facility.

As German cannabis markets change, SOMAÍ will be there to increasingly bring innovative products. The SOMAÍ plus Grünhorn and Canymed partnership will stand the test of time and show all players to be a great model for today and the future. After all, it’s about the patient experience, and both companies agree that delivering consistent quality and innovation helps expand consumer demographics.